Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Abstract
Mutations in members of the RAS family of small GTPases have been associated with numerous human cancers. However, RAS family members are notoriously difficult to target. In this issue of Structure, Lu et al. (2017) examine the effects of two compounds with distinct chemical scaffolds on the structure and dynamics of an oncogenic KRAS mutant, thus highlighting the usefulness of HDX-MS for drug development.Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028695525&doi=10.1016%2fj.str.2017.08.012&partnerID=40&md5=4e79059861be93671e9452b3d6b89034; http://hdl.handle.net/10713/10950ae974a485f413a2113503eed53cd6c53
10.1016/j.str.2017.08.012
Scopus Count
Collections
Related articles
- KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry.
- Authors: Lu J, Harrison RA, Li L, Zeng M, Gondi S, Scott D, Gray NS, Engen JR, Westover KD
- Issue date: 2017 Sep 5
- Defining the First Part of the Oncogenic KRAS Journey.
- Authors: Osborne JK, Minna JD
- Issue date: 2020 Oct 1
- Mutant RAS Calms Stressed-Out Cancer Cells.
- Authors: Bryant KL, Der CJ
- Issue date: 2017 Jan 23
- T-Cell Transfer Therapy Targeting Mutant KRAS.
- Authors: Maoz A, Rennert G, Gruber SB
- Issue date: 2017 Feb 16
- T-Cell Transfer Therapy Targeting Mutant KRAS.
- Authors: Rech AJ, Vonderheide RH
- Issue date: 2017 Feb 16